Cost Effectiveness of Self-Expanding Valve Driven by Improved Quality of Life Benefit and Superior One-Year Survival Rates over Surgical Aortic Valve Replacement. WASHINGTON, D.C., and MINNEAPOLIS – Sept. 13, 2014 – In the first-ever in-trial cost effectiveness analysis of transcatheter aortic valve replacement (TAVR) for patients at high risk for surgery, investigators today revealed new data demonstrating the cost effectiveness of the CoreValve® System from Medtronic, Inc. (NYSE: MDT) for high risk patients with severe aortic stenosis. The economic analysis used data from the CoreValve U.S. Pivotal Trial’s study of high risk patients, which is the only head-to-head study to show the superiority of TAVR to traditional surgical aortic valve replacement (SAVR) at one year. The new data were presented during a late-breaking session at Transcatheter Cardiovascular Therapeutics (TCT) 2014.
BARCELONA, Spain – Sunday 31 August: The investigational drug alirocumab significantly improved cholesterol levels compared to ezetimibe, when added to regular statin therapy in patients with high cholesterol and elevated risk of cardiovascular disease (CVD), according to the ODYSSEY COMBO II trial, presented as a Hot Line today at ESC Congress 2014.
Excited for TCT 2014? HCRI has been busy at work prepping for this year’s show! Come check out our newly expanded booth #2139 to chat with our staff and faculty on what we've been up to over the last year. This year's agenda will include case sessions from Dr. Laura Mauri, Dr. Robert Yeh, Dr. Don Cutlip, and others. We look forward to seeing everyone in DC!
A new study from HCRI highlights the importance of post market surveillance stent studies to depict safety signals. Postmarket surveillance of zotarolimus-eluting stents shows similar efficacy compared with premarket studies despite differences in patient populations but finds higher risk of myocardial infarction (MI), according to a paper published online June 9, 2014, in the American Journal of Cardiology.